EXAS: Exact Sciences Corporation Stock

by  •  • Comments Off on EXAS: Exact Sciences Corporation Stock

SIC 8071 – Medical Laboratories

Valuation
Market Cap ($M) 11,474.57
Enterprise Value ($M) 13,233.47
Book Value ($M) 3,145.30
Book Value / Share 17.33
Price / Book 3.65
NCAV ($M) -2,131.66
NCAV / Share -11.74
Price / NCAV -5.38

Profitability (mra)
Return on Invested Capital (ROIC) -0.04
Return on Assets (ROA) -0.03
Return on Equity (ROE) -0.07

Liquidity (mrq)
Quick Ratio 2.07
Current Ratio 2.32

Balance Sheet (mrq) ($M)
Current Assets 1,194.37
Assets 6,471.33
Liabilities 3,326.03
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,499.77
Operating Income -214.39
Net Income -204.15
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 156.12
Cash from Investing 49.68
Cash from Financing 159.77

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 9.71 1.78
02-09 13G/A Wellington Management Group Llp 5.83 1.27
01-29 13G/A BlackRock Inc. 6.10 -2.21
01-23 13G/A Jpmorgan Chase & Co 9.50 -7.02

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECT
2023-11-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-17 737,442 799,323 92.26
2024-04-16 610,884 1,136,438 53.75
2024-04-15 661,181 1,110,345 59.55
2024-04-12 555,844 965,530 57.57

(click for more detail)

Similar Companies
BGLC – BioNexus Gene Lab Corp. CELC – Celcuity Inc.
DMTK – DermTech, Inc. MDXH – MDxHealth SA
OPGN – OpGen, Inc.


Financial data and stock pages provided by
Fintel.io